ArticleScientific reports2026
The role of CUEDC1 in suppressing JAK1/STAT3 signaling pathway in esophageal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
CUE domain containing protein 1 (CUEDC1) is implicated in tumor progression; however, its specific role in esophageal cancer (ESCA) remains unclear. In esophageal cancer, the expression of CUEDC1 is notably low, which correlates with reduced survival rates and adverse clinical outcomes. Overexpression of CUEDC1 results in decreased activity of the JAK1/STAT3 signaling pathway in cells, consequently diminishing their proliferation, migration, and invasion capabilities. This mechanism operates through the direct binding of CUEDC1 to STAT3, facilitating its ubiquitination and triggering the ubiquitin-proteasome degradation pathway, ultimately leading to a significant reduction in intracellular STAT3 levels. This study suggests that CUEDC1 can reduce intracellular STAT3 protein levels, thereby inhibiting JAK1/STAT3 signaling transduction and suppressing the progression of ESCA. This study aims to elucidate the regulatory mechanism of CUEDC1 on STAT3, which will enhance our understanding of the regulatory pathways involved in the treatment of esophageal cancer and potentially other tumors. Future breakthroughs and innovations may emerge from molecular research and development targeting this pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.